Compare CAPR & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | LILAK |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | Bermuda |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2011 | N/A |
| Metric | CAPR | LILAK |
|---|---|---|
| Price | $19.50 | $7.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $44.63 | $8.20 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $4.75 |
| 52 Week High | $40.37 | $9.13 |
| Indicator | CAPR | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 28.96 | 49.35 |
| Support Level | $5.25 | $6.85 |
| Resistance Level | $30.39 | $8.21 |
| Average True Range (ATR) | 1.33 | 0.31 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 16.93 | 34.65 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.